항체약물접합체(ADC) 시장 규모, 점유율, 성장률, 세계 업계 분석, 지역별 동향 및 예측(2026-2034년)

Growth Factors of Antibody Drug Conjugates (ADC) Market

The global Antibody Drug Conjugates (ADC) market was valued at USD 18.60 billion in 2025 and is projected to grow from USD 22.60 billion in 2026 to USD 68.00 billion by 2034, registering a strong CAGR of 14.76% during the forecast period (2026-2034). North America dominated the market with a 51.83% share in 2025, supported by high adoption of advanced oncology therapies, strong healthcare infrastructure, and continuous regulatory approvals for novel ADC products.

Antibody Drug Conjugates are targeted cancer therapies that combine monoclonal antibodies with highly potent cytotoxic drugs. These therapies selectively target cancer cells while minimizing damage to healthy tissues, making them a preferred treatment option in modern oncology. Increasing prevalence of cancer, growing demand for precision medicine, rising biomarker-based diagnostics, and continuous advancements in linker and payload technologies are driving market expansion worldwide.

Market Overview

The ADC industry is witnessing remarkable growth as pharmaceutical companies focus on developing next-generation targeted therapies. ADCs are increasingly being used in breast cancer, urothelial cancer, lymphoma, lung cancer, ovarian cancer, and gastric cancer treatments. Enhanced linker stability, improved drug-to-antibody ratios, and innovative payload technologies are improving treatment outcomes and expanding therapeutic applications.

Major market participants include Daiichi Sankyo Company, AstraZeneca, Pfizer Inc., Astellas Pharma Inc., Gilead Sciences, Inc., and F. Hoffmann-La Roche Ltd., all of which are investing heavily in research, acquisitions, and strategic collaborations.

Market Trends

Development of Next-Generation ADCs

A significant trend shaping the market is the development of advanced ADC platforms featuring:

• Site-specific conjugation technologies
• Dual-payload ADCs
• Improved linker stability
• Enhanced tumor targeting capabilities
• Higher drug-to-antibody ratios

These innovations are helping ADCs move beyond traditional targets such as HER2 and CD30 to emerging targets including TROP2, CLDN6/9, CDH17, and VEGF.

Market Drivers

Growing Adoption of Targeted Cancer Therapies

Healthcare providers are increasingly shifting from conventional chemotherapy toward precision oncology treatments. ADCs offer improved efficacy with reduced systemic toxicity, making them attractive treatment options for patients and physicians.

The growing use of biomarker testing allows better patient selection for ADC therapies targeting HER2, TROP2, Nectin-4, CD30, and Folate Receptor Alpha, further supporting market growth.

Market Restraints

High Research and Development Costs

ADC development requires significant investments in:

• Antibody engineering
• Linker development
• Cytotoxic payload optimization
• Clinical trials
• Specialized manufacturing

The complexity and cost of development create barriers for smaller biotechnology companies and may limit market expansion.

Market Opportunities

Rising Investments in Oncology Drug Development

Growing investments from pharmaceutical companies and venture capital firms are creating major opportunities in the ADC market. Companies are accelerating clinical trials, exploring new cancer indications, and expanding next-generation ADC pipelines.

The increasing number of licensing agreements, partnerships, and acquisitions is expected to strengthen future market growth.

Market Challenges

Limited Specialized Manufacturing Capacity

ADC manufacturing requires highly specialized facilities capable of handling potent cytotoxic compounds under strict containment conditions. Limited availability of such facilities can create supply bottlenecks and increase production costs, posing a challenge to market expansion.

Segmentation Analysis

By Product/Target Family

The HER2-directed ADCs segment dominated the market in 2025 due to the commercial success of products such as Enhertu and Kadcyla. Strong adoption in breast and gastric cancers continues to support segment growth.

The Folate Receptor Alpha-directed ADCs segment is projected to witness the fastest growth, expanding at a CAGR of 27.09% through 2034.

By Payload Class

The Microtubule Inhibitor ADCs segment held the largest market share in 2025 and is expected to account for 36.3% of the market in 2026. Its dominance is supported by approved therapies such as Adcetris, Padcev, Kadcyla, Polivy, and Tivdak.

By Disease Indication

The Breast Cancer segment led the market in 2025 due to widespread use of ADCs in HER2-positive and HER2-low breast cancer treatment. The segment is expected to hold 39.0% market share in 2026.

By Route of Administration

The Intravenous segment dominated the market and is projected to account for 99.7% of total revenue in 2026, as nearly all approved ADC therapies are administered through IV infusion.

By End User

The Hospitals segment held the largest market share in 2025 and is expected to maintain 51.9% share in 2026 due to the availability of specialized oncology infrastructure and infusion facilities.

Regional Analysis

North America

North America remained the largest regional market with a value of USD 9.64 billion in 2025. Strong reimbursement systems, high cancer treatment expenditure, and rapid adoption of innovative oncology therapies support regional leadership.

United States

The U.S. ADC market is projected to reach USD 10.66 billion in 2026, accounting for approximately 47.2% of global revenue.

Europe

Europe is expected to register a CAGR of 13.95% during the forecast period. Growing use of targeted therapies and favorable reimbursement frameworks continue to support market expansion.

Germany is expected to reach USD 1.11 billion in 2026, while the U.K. market is projected at USD 0.69 billion.

Asia Pacific

Asia Pacific is anticipated to reach USD 4.74 billion in 2026, driven by increasing healthcare spending, rising cancer prevalence, and improved access to advanced oncology treatments.

Japan and China are each expected to generate approximately USD 1.54 billion in revenue in 2026, while India is projected to reach USD 0.25 billion.

Latin America and Middle East & Africa

These regions are witnessing gradual adoption of advanced cancer therapies. Latin America is expected to reach USD 0.87 billion in 2026, while the GCC market is projected at USD 0.21 billion.

Competitive Landscape

The antibody drug conjugates market is semi-consolidated, with major companies focusing on product approvals, pipeline expansion, acquisitions, and strategic collaborations.

Leading companies include:

• Daiichi Sankyo Company, Limited
• AstraZeneca
• Pfizer Inc.
• Gilead Sciences, Inc.
• F. Hoffmann-La Roche Ltd.
• AbbVie Inc.
• GSK plc
• RemeGen
• Astellas Pharma Inc.
• Jiangsu Hengrui Pharmaceuticals Co., Ltd.

Recent industry developments include Gilead's acquisition of Tubulis in April 2026, Eli Lilly's acquisition of CrossBridge Bio in April 2026, and AstraZeneca's USD 1.5 billion ADC manufacturing facility investment in Singapore.

Conclusion

The global antibody drug conjugates market is entering a period of rapid expansion driven by increasing adoption of precision oncology, rising cancer prevalence, and continuous innovation in ADC technology. Valued at USD 18.60 billion in 2025, the market is expected to grow to USD 22.60 billion in 2026 and reach USD 68.00 billion by 2034. Advances in next-generation ADC platforms, growing investments in oncology drug development, expanding treatment indications, and increasing regulatory approvals will continue to create substantial growth opportunities for market participants throughout the forecast period.

Segmentation By Product/Target Family, Payload Class, Disease Indication, Route of Administration, End User, and Region

By Product/Target Family * HER2-directed ADCs

• Nectin-4-directed ADCs
• TROP2-directed ADCs
• CD30-directed ADCs
• CD79b-directed ADCs
• Folate Receptor Alpha-directed ADCs
• Others

By Payload Class * Topoisomerase I Inhibitor ADCs

• Microtubule Inhibitor ADCs
• Maytansinoid ADCs
• DNA-damaging ADCs
• Others

By Disease Indication * Breast Cancer

• Urothelial Cancer
• Lymphoma
• Lung Cancer
• Ovarian Cancer
• Gastric & Gastroesophageal Cancer
• Others

By Route of Administration * Intravenous

• Others

By End User * Hospitals

• Cancer Specialty Centers
• Academic & Research Hospitals
• Ambulatory Infusion Centers
• Others

By Region * North America (By Product/Target Family, Payload Class, Disease Indication, Route of Administration, End User, and Country)

• U.S.
• Canada
• Europe (By Product/Target Family, Payload Class, Disease Indication, Route of Administration, End User, and Country/Sub-region)
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Product/Target Family, Payload Class, Disease Indication, Route of Administration, End User, and Country/Sub-region)
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Product/Target Family, Payload Class, Disease Indication, Route of Administration, End User, and Country/Sub-region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Product/Target Family, Payload Class, Disease Indication, Route of Administration, End User, and Country/Sub-region)
  • GCC
  • South Africa
  • Rest of Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Challenges
• 3.5. Market Trends

4. Key Insights

• 4.1. Technological Advancements in Antibody Drug Conjugates
• 4.2. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
• 4.3. New Product Launches, By Key Players
• 4.4. Pipeline Analysis, By Key Players
• 4.5. Regulatory & Reimbursement Scenario, By Key Countries/Region

5. Global Antibody Drug Conjugates Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Product/Target Family
  • 5.1.1. HER2-directed ADCs
  • 5.1.2. Nectin-4-directed ADCs
  • 5.1.3. TROP2-directed ADCs
  • 5.1.4. CD30-directed ADCs
  • 5.1.5. CD79b-directed ADCs
  • 5.1.6. Folate Receptor Alpha-directed ADCs
  • 5.1.7. Others
• 5.2. Market Analysis, Insights and Forecast - By Payload Class
  • 5.2.1. Topoisomerase I Inhibitor ADCs
  • 5.2.2. Microtubule Inhibitor ADCs
  • 5.2.3. Maytansinoid ADCs
  • 5.2.4. DNA-damaging ADCs
  • 5.2.5. Others
• 5.3. Market Analysis, Insights and Forecast - By Disease Indication
  • 5.3.1. Breast Cancer
  • 5.3.2. Urothelial Cancer
  • 5.3.3. Lymphoma
  • 5.3.4. Lung Cancer
  • 5.3.5. Ovarian Cancer
  • 5.3.6. Gastric & Gastroesophageal Cancer
  • 5.3.7. Others
• 5.4. Market Analysis, Insights and Forecast - By Route of Administration
  • 5.4.1. Intravenous
  • 5.4.2. Others
• 5.5. Market Analysis, Insights and Forecast - By End User
  • 5.5.1. Hospitals
  • 5.5.2. Cancer Specialty Centers
  • 5.5.3. Academic & Research Hospitals
  • 5.5.4. Ambulatory Infusion Centers
  • 5.5.5. Others
• 5.6. Market Analysis, Insights and Forecast - Region
  • 5.6.1. North America
  • 5.6.2. Europe
  • 5.6.3. Asia Pacific
  • 5.6.4. Latin America
  • 5.6.5. Middle East & Africa

6. North America Antibody Drug Conjugates Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Product/Target Family
  • 6.1.1. HER2-directed ADCs
  • 6.1.2. Nectin-4-directed ADCs
  • 6.1.3. TROP2-directed ADCs
  • 6.1.4. CD30-directed ADCs
  • 6.1.5. CD79b-directed ADCs
  • 6.1.6. Folate Receptor Alpha-directed ADCs
  • 6.1.7. Others
• 6.2. Market Analysis, Insights and Forecast - By Payload Class
  • 6.2.1. Topoisomerase I Inhibitor ADCs
  • 6.2.2. Microtubule Inhibitor ADCs
  • 6.2.3. Maytansinoid ADCs
  • 6.2.4. DNA-damaging ADCs
  • 6.2.5. Others
• 6.3. Market Analysis, Insights and Forecast - By Disease Indication
  • 6.3.1. Breast Cancer
  • 6.3.2. Urothelial Cancer
  • 6.3.3. Lymphoma
  • 6.3.4. Lung Cancer
  • 6.3.5. Ovarian Cancer
  • 6.3.6. Gastric & Gastroesophageal Cancer
  • 6.3.7. Others
• 6.4. Market Analysis, Insights and Forecast - By Route of Administration
  • 6.4.1. Intravenous
  • 6.4.2. Others
• 6.5. Market Analysis, Insights and Forecast - By End User
  • 6.5.1. Hospitals
  • 6.5.2. Cancer Specialty Centers
  • 6.5.3. Academic & Research Hospitals
  • 6.5.4. Ambulatory Infusion Centers
  • 6.5.5. Others
• 6.6. Market Analysis, Insights and Forecast - By Country
  • 6.6.1. U.S.
  • 6.6.2. Canada

7. Europe Antibody Drug Conjugates Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Product/Target Family
  • 7.1.1. HER2-directed ADCs
  • 7.1.2. Nectin-4-directed ADCs
  • 7.1.3. TROP2-directed ADCs
  • 7.1.4. CD30-directed ADCs
  • 7.1.5. CD79b-directed ADCs
  • 7.1.6. Folate Receptor Alpha-directed ADCs
  • 7.1.7. Others
• 7.2. Market Analysis, Insights and Forecast - By Payload Class
  • 7.2.1. Topoisomerase I Inhibitor ADCs
  • 7.2.2. Microtubule Inhibitor ADCs
  • 7.2.3. Maytansinoid ADCs
  • 7.2.4. DNA-damaging ADCs
  • 7.2.5. Others
• 7.3. Market Analysis, Insights and Forecast - By Disease Indication
  • 7.3.1. Breast Cancer
  • 7.3.2. Urothelial Cancer
  • 7.3.3. Lymphoma
  • 7.3.4. Lung Cancer
  • 7.3.5. Ovarian Cancer
  • 7.3.6. Gastric & Gastroesophageal Cancer
  • 7.3.7. Others
• 7.4. Market Analysis, Insights and Forecast - By Route of Administration
  • 7.4.1. Intravenous
  • 7.4.2. Others
• 7.5. Market Analysis, Insights and Forecast - By End User
  • 7.5.1. Hospitals
  • 7.5.2. Cancer Specialty Centers
  • 7.5.3. Academic & Research Hospitals
  • 7.5.4. Ambulatory Infusion Centers
  • 7.5.5. Others
• 7.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 7.6.1. U.K.
  • 7.6.2. Germany
  • 7.6.3. France
  • 7.6.4. Italy
  • 7.6.5. Spain
  • 7.6.6. Scandinavia
  • 7.6.7. Rest of Europe

8. Asia Pacific Antibody Drug Conjugates Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Product/Target Family
  • 8.1.1. HER2-directed ADCs
  • 8.1.2. Nectin-4-directed ADCs
  • 8.1.3. TROP2-directed ADCs
  • 8.1.4. CD30-directed ADCs
  • 8.1.5. CD79b-directed ADCs
  • 8.1.6. Folate Receptor Alpha-directed ADCs
  • 8.1.7. Others
• 8.2. Market Analysis, Insights and Forecast - By Payload Class
  • 8.2.1. Topoisomerase I Inhibitor ADCs
  • 8.2.2. Microtubule Inhibitor ADCs
  • 8.2.3. Maytansinoid ADCs
  • 8.2.4. DNA-damaging ADCs
  • 8.2.5. Others
• 8.3. Market Analysis, Insights and Forecast - By Disease Indication
  • 8.3.1. Breast Cancer
  • 8.3.2. Urothelial Cancer
  • 8.3.3. Lymphoma
  • 8.3.4. Lung Cancer
  • 8.3.5. Ovarian Cancer
  • 8.3.6. Gastric & Gastroesophageal Cancer
  • 8.3.7. Others
• 8.4. Market Analysis, Insights and Forecast - By Route of Administration
  • 8.4.1. Intravenous
  • 8.4.2. Others
• 8.5. Market Analysis, Insights and Forecast - By End User
  • 8.5.1. Hospitals
  • 8.5.2. Cancer Specialty Centers
  • 8.5.3. Academic & Research Hospitals
  • 8.5.4. Ambulatory Infusion Centers
  • 8.5.5. Others
• 8.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 8.6.1. China
  • 8.6.2. Japan
  • 8.6.3. India
  • 8.6.4. Australia
  • 8.6.5. Southeast Asia
  • 8.6.6. Rest of Asia Pacific

9. Latin America Antibody Drug Conjugates Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Product/Target Family
  • 9.1.1. HER2-directed ADCs
  • 9.1.2. Nectin-4-directed ADCs
  • 9.1.3. TROP2-directed ADCs
  • 9.1.4. CD30-directed ADCs
  • 9.1.5. CD79b-directed ADCs
  • 9.1.6. Folate Receptor Alpha-directed ADCs
  • 9.1.7. Others
• 9.2. Market Analysis, Insights and Forecast - By Payload Class
  • 9.2.1. Topoisomerase I Inhibitor ADCs
  • 9.2.2. Microtubule Inhibitor ADCs
  • 9.2.3. Maytansinoid ADCs
  • 9.2.4. DNA-damaging ADCs
  • 9.2.5. Others
• 9.3. Market Analysis, Insights and Forecast - By Disease Indication
  • 9.3.1. Breast Cancer
  • 9.3.2. Urothelial Cancer
  • 9.3.3. Lymphoma
  • 9.3.4. Lung Cancer
  • 9.3.5. Ovarian Cancer
  • 9.3.6. Gastric & Gastroesophageal Cancer
  • 9.3.7. Others
• 9.4. Market Analysis, Insights and Forecast - By Route of Administration
  • 9.4.1. Intravenous
  • 9.4.2. Others
• 9.5. Market Analysis, Insights and Forecast - By End User
  • 9.5.1. Hospitals
  • 9.5.2. Cancer Specialty Centers
  • 9.5.3. Academic & Research Hospitals
  • 9.5.4. Ambulatory Infusion Centers
  • 9.5.5. Others
• 9.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 9.6.1. Brazil
  • 9.6.2. Mexico
  • 9.6.3. Rest of Latin America

10. Middle East & Africa Antibody Drug Conjugates Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Product/Target Family
  • 10.1.1. HER2-directed ADCs
  • 10.1.2. Nectin-4-directed ADCs
  • 10.1.3. TROP2-directed ADCs
  • 10.1.4. CD30-directed ADCs
  • 10.1.5. CD79b-directed ADCs
  • 10.1.6. Folate Receptor Alpha-directed ADCs
  • 10.1.7. Others
• 10.2. Market Analysis, Insights and Forecast - By Payload Class
  • 10.2.1. Topoisomerase I Inhibitor ADCs
  • 10.2.2. Microtubule Inhibitor ADCs
  • 10.2.3. Maytansinoid ADCs
  • 10.2.4. DNA-damaging ADCs
  • 10.2.5. Others
• 10.3. Market Analysis, Insights and Forecast - By Disease Indication
  • 10.3.1. Breast Cancer
  • 10.3.2. Urothelial Cancer
  • 10.3.3. Lymphoma
  • 10.3.4. Lung Cancer
  • 10.3.5. Ovarian Cancer
  • 10.3.6. Gastric & Gastroesophageal Cancer
  • 10.3.7. Others
• 10.4. Market Analysis, Insights and Forecast - By Route of Administration
  • 10.4.1. Intravenous
  • 10.4.2. Others
• 10.5. Market Analysis, Insights and Forecast - By End User
  • 10.5.1. Hospitals
  • 10.5.2. Cancer Specialty Centers
  • 10.5.3. Academic & Research Hospitals
  • 10.5.4. Ambulatory Infusion Centers
  • 10.5.5. Others
• 10.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 10.6.1. GCC
  • 10.6.2. South Africa
  • 10.6.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. DAIICHI SANKYO COMPANY, LIMITED
  • 11.2.2. AstraZeneca
  • 11.2.3. Pfizer Inc.
  • 11.2.4. Gilead Sciences, Inc.
  • 11.2.5. F. Hoffmann-La Roche Ltd
  • 11.2.6. AbbVie Inc.
  • 11.2.7. GSK plc
  • 11.2.8. RemeGen
  • 11.2.9. Astellas Pharma Inc.
  • 11.2.10. Jiangsu Hengrui Pharmaceuticals Co., Ltd.